Zheng S, Hu GY, Li JH, Li YK. Potential plausible role of Wharton’s jelly mesenchymal stem cells for diabetic bone regeneration. World J Stem Cells 2024; 16(8): 824-826 [DOI: 10.4252/wjsc.v16.i8.824]
Corresponding Author of This Article
Yi-Kai Li, MD, PhD, Chief Physician, Full Professor, Research Scientist, Department of Traditional Chinese Orthopedics and Traumatology, Center for Orthopedic Surgery, The Third Affiliated Hospital of Southern Medical University, No. 183 Zhongshan Avenue West, Tianhe District, Guangzhou 510630, Guangdong Province, China. ortho@smu.edu.cn
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Stem Cells. Aug 26, 2024; 16(8): 824-826 Published online Aug 26, 2024. doi: 10.4252/wjsc.v16.i8.824
Potential plausible role of Wharton’s jelly mesenchymal stem cells for diabetic bone regeneration
Sheng Zheng, Guan-Yu Hu, Jun-Hua Li, Yi-Kai Li
Sheng Zheng, Guan-Yu Hu, Yi-Kai Li, Department of Traditional Chinese Orthopedics and Traumatology, Center for Orthopedic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510630, Guangdong Province, China
Jun-Hua Li, School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, Guangdong Province, China
Author contributions: Zheng S and Li YK wrote the original draft; Zheng S, Hu GY, Li JH, and Li YK contributed to conceptualization, writing, reviewing and editing. All authors have read and approved the final version of the manuscript.
Supported byChina Postdoctoral Science Foundation, No. 2024M751344; and the Postdoctoral Fellowship Program of China Postdoctoral Science Foundation, No. GZC20231088.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yi-Kai Li, MD, PhD, Chief Physician, Full Professor, Research Scientist, Department of Traditional Chinese Orthopedics and Traumatology, Center for Orthopedic Surgery, The Third Affiliated Hospital of Southern Medical University, No. 183 Zhongshan Avenue West, Tianhe District, Guangzhou 510630, Guangdong Province, China. ortho@smu.edu.cn
Received: August 1, 2024 Revised: August 11, 2024 Accepted: August 22, 2024 Published online: August 26, 2024 Processing time: 24 Days and 20.9 Hours
Abstract
This letter addresses the review titled “Wharton’s jelly mesenchymal stem cells: Future regenerative medicine for clinical applications in mitigation of radiation injury”. The review highlights the regenerative potential of Wharton’s jelly mesenchymal stem cells (WJ-MSCs) and describes why WJ-MSCs will become one of the most probable stem cells for future regenerative medicine. The potential plausible role of WJ-MSCs for diabetic bone regeneration should be noticeable, which will provide a new strategy for improving bone regeneration under diabetic conditions.
Core Tip: Both osteogenesis and angiogenesis are closely related to bone regeneration. Diabetes mellitus normally impairs angiogenesis, which leads to diabetic bone regeneration deficiency. Wharton’s jelly mesenchymal stem cells not only possess the ability to differentiation into osteoblasts, but also produce a crucial secretory factor (vascular endothelial growth factor) to promote angiogenesis. Thus, Wharton’s jelly mesenchymal stem cell is expected to exert more vital role in improving diabetic bone regeneration.
